Reported a consolidated net loss of $59.6 million for the year ended December 31, 2025, compared to $69.8 million in 2024. Accumulated deficit reached $545.6 million as of December 31, 2025. Cash and cash equivalents totaled $7.1 million as of December 31, 2025, which are not sufficient to fund operations past the first half of 2026, raising substantial doubt about the company's ability to continue as a going concern. Initiated a formal process on March 2, 2026, to explore strategic options, including asset sales, licensing, partnerships, or other corporate transactions. Implemented a restructuring plan on March 2, 2026, involving a workforce reduction of approximately 70% and other cost-containment measures. Re-evaluating the timing and scope of clinical development programs, including additional enrollment in the Phase 1 study of BA3182 and the timeline to commence a Phase 3 study for ozuriftamab vedotin (BA3021). Received a delist determination from Nasdaq on August 6, 2025, for non-compliance with minimum bid price and stockholders' equity requirements; the company's common stock continues to trade pending a Listing Council review. Stockholders approved a merger and a 1-for-50 reverse stock split (Share Consolidation) on March 23, 2026, expected to be effective April 6, 2026, to help regain Nasdaq compliance.